Commit Biologics Email Format

Biotechnology ResearchCentral Jutland, Denmark11-50 Employees

Commit Biologics is a biotechnology research company focused on activating the complement system to destroy targeted cells, with potential applications in cancer and autoimmune diseases. Based in Aarhus, Central Jutland, it originated as a spin-out from Aarhus University and draws on more than three decades of foundational research. Its Bispecific Complement Engaging (BiCE) platform augments a conventional monoclonal antibody by guiding C1q to initiate the complement cascade against a chosen cell target. The BiCE approach uses modular components to enable therapeutics across multiple tumor-associated antigens and immune cell targets, reflecting an emphasis on leveraging direct cytolysis alongside recruitment of innate and adaptive immune responses. In March 2026, Commit Biologics appointed Thomas L. F. Montgomery Andresen as chief executive officer, indicating a leadership transition.

Sign up for free to view info

Company overview Employee directory